Chen K, Feng X, Shi Y, Li XL, Shi ZR, Lan X. Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature. World J Gastrointest Oncol 2025; 17(1): 98433 [DOI: 10.4251/wjgo.v17.i1.98433]
Corresponding Author of This Article
Xiang Lan, PhD, Chief Doctor, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Youyi Road, Yuzhong District, Chongqing 400016, China. lanxiang_tmmu@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 98433 Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature
Kai Chen, Xu Feng, Yuan Shi, Xin-Lin Li, Zheng-Rong Shi, Xiang Lan
Kai Chen, Xu Feng, Yuan Shi, Xin-Lin Li, Zheng-Rong Shi, Xiang Lan, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Author contributions: Chen K conducted the literature review and contributed to manuscript drafting and data interpretation; Feng X collected all clinical data and evaluated the examination results; Shi Y assisted in data collection and analysis; Li XL was responsible for revising the manuscript for important intellectual content; Shi ZR contributed to the study design and methodology; Lan X served as the corresponding author, overseeing the overall direction and final approval of the manuscript for submission and publication.
Supported by General Project of Natural Science Foundation of Chongqing, China, No. cstc2021jcyj-msxmX0604; and Chongqing Doctoral "Through Train" Research Program, China, No. CSTB2022BSXM-JCX0045.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiang Lan, PhD, Chief Doctor, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Youyi Road, Yuzhong District, Chongqing 400016, China. lanxiang_tmmu@163.com
Received: June 26, 2024 Revised: October 10, 2024 Accepted: November 4, 2024 Published online: January 15, 2025 Processing time: 169 Days and 5.8 Hours
Abstract
BACKGROUND
Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab shows promise for the treatment of advanced BTC. However, the efficacy of this treatment for GBC remains unclear.
CASE SUMMARY
In this report, we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC, thus leading to a long-term survival benefit. A 68-year-old man was diagnosed with locally advanced GBC, which rendered him ineligible for curative surgery. Following three cycles of therapy, a partial response was observed. After one year of combined therapy, a clinical complete response was successfully achieved. Subsequent maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the patient. The patient experienced tolerable toxicities of reversible grade 2 nausea and fatigue. Tolerable adverse events were observed in the patient throughout the entirety of the treatment.
CONCLUSION
The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC, with manageable adverse events. Further research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.
Core Tip: This study presents a significant case of a patient with locally advanced gallbladder cancer (GBC) who achieved a clinical complete response following treatment with a novel regimen combining gemcitabine, cisplatin, and durvalumab (GC-D). Despite the notorious resistance of GBC to conventional therapies, the positive outcomes observed in this case suggest potential benefits of immunotherapy in this context. These findings highlight the need for further research to validate the efficacy of the GC-D regimen and to explore its implications for future treatment protocols in GBC.
